celltrion syringe brazil
Scope
Date
~
-
Bio & Pharma
Celltrion gets FDA approval for Humira biosimilar CT-P17
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...
May 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches Remsima SC in Brazil
South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseas...
May 22, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion drops bid to acquire Baxter’s biopharm unit
Celltrion Inc. announced on Tuesday it has decided not to pursue the acquisition of the biopharmaceutical unit of U.S. medical device maker Baxter I...
May 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for Phase 3 clinical trials in Europe for biosimilar
South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...
May 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...
Apr 21, 2023 (Gmt+09:00)
-
Private equity
MBK Partners co-founder tops 50 richest S.Koreans: Forbes
Michael ByungJu Kim, co-founder and partner at private equity firm MBK Partners, has topped the ranking of the 50 richest South Koreans by net worth...
Apr 18, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Celltrion Healthcare launches Vegzelma in US
South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorecta...
Apr 17, 2023 (Gmt+09:00)
-
Bio & Pharma
Biosimilar giant Celltrion to transform into drug developer
South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is...
Mar 29, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion founder returns to management with M&A pledge
South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to mer...
Mar 28, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion eyes Baxter's arm as it gears up for M&As
Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...
Mar 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Genuv sign agreement for antibody joint R&D
South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday a joint research and development agreement with Genuv, Inc., a domestic drug...
Mar 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion ex-Chairman Seo set to return to management; group stocks rally
South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...
Mar 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion teams up with bio venture to develop new anti-cancer drug
South Korea's biopharmaceutical company Celltrion Inc. will develop an anti-cancer drug that combines oncolytic virus technology with biosimilars un...
Feb 28, 2023 (Gmt+09:00)
-
Bio & Pharma
Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico
South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exportin...
Feb 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Brazil approves Celltrion Pharm’s syringe facility
Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...
Feb 20, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Hwajin Medical gets FDA sales approval for syringes
HLB Therapeutics Co. announced Thursday that Sofjec, a syringe produced by its subsidiary Hwajin Medical, has been approved for sale by the US Food ...
Feb 17, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Truxima shows safety, efficacy in post-marketing study
South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...
Feb 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Nibec gets approval for its bone graft biomaterials in Colombia, Mexico
South Korea's bioactive peptide technology company Nibec Co. said on Friday that it has obtained product approval for the sale of two types of denta...
Jan 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan
Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion increases its stake in British ADC developer Iksuda
Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...
Jan 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year
South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to tre...
Jan 11, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion acquires approval to sell Vegzelma in Canada
South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Chemical Industry
FarmHannong's herbicide Terrad'or enters Brazil
FarmHannong, South Korea's leading agricultural chemicals producer, said on Tuesday that its new herbicide Terrad'or has been registered as a new he...
Dec 27, 2022 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Lunit exports AI imaging analysis solution to Brazil
South Korea's medical imaging startup Lunit said on Monday it has signed a software licensing agreement with Albert Einstein Israelite Hospital in...
Dec 19, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion to seek FDA approval for sale of Remsima SC by year-end
Celltrion Inc. said it has confirmed the effectiveness and safety of Remsima SC in its third-phase global clinical trials, conducted on 438 patients...
Nov 28, 2022 (Gmt+09:00)